Hypogonadism and Sexual Dysfunction in Testicular Tumor Survivors: A Systematic Review.
cardiovascular risk
hypogonadism
sexual dysfunction
testicular tumor
testosterone
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2019
2019
Historique:
received:
29
01
2019
accepted:
09
04
2019
entrez:
29
5
2019
pubmed:
28
5
2019
medline:
28
5
2019
Statut:
epublish
Résumé
Testicular tumor is the most common malignancy in men of reproductive age. According to the tumor histology and staging, current treatment options include orchiectomy alone or associated with adjuvant chemo- and/or radiotherapy. Although these treatments have considerably raised the percentage of survivors compared to the past, they have been identified as risk factors for testosterone deficiency and sexual dysfunction in this subgroup of men. Male hypogonadism, in turn, predisposes to the development of metabolic and cardiovascular impairment that negatively affects general health. Accordingly, longitudinal studies report a long-term risk for cardiovascular diseases after radiotherapy and/or cisplatin-based chemotherapy in testicular tumor survivors. The aim of this review was to summarize the current evidence on hypogonadism and sexual dysfunction in long-term cancer survivors, including the epidemiology of cardiovascular and metabolic disorders, to increase the awareness that serum testosterone levels, sexual function, and general health should be evaluated during the endocrinological management of these patients.
Identifiants
pubmed: 31133982
doi: 10.3389/fendo.2019.00264
pmc: PMC6513875
doi:
Types de publication
Journal Article
Langues
eng
Pagination
264Commentaires et corrections
Type : ErratumIn
Références
Basic Clin Pharmacol Toxicol. 2008 Feb;102(2):155-61
pubmed: 18226069
J Clin Oncol. 2018 May 20;36(15):1505-1512
pubmed: 29617189
Arch Ital Urol Androl. 2016 Oct 05;88(3):186-188
pubmed: 27711091
J Psychosom Res. 2012 Jul;73(1):68-73
pubmed: 22691563
J Clin Oncol. 2010 Oct 20;28(30):4649-57
pubmed: 20855830
J Urol. 1998 Jun;159(6):1947-50
pubmed: 9598494
Eur Rev Med Pharmacol Sci. 2009 Sep-Oct;13(5):351-6
pubmed: 19961040
Urology. 2009 Oct;74(4):825-9
pubmed: 19589582
Med Oncol. 2014 Jul;31(7):43
pubmed: 24913808
Eur J Cancer. 1995;31A(5):739-46
pubmed: 7640048
Andrology. 2016 May;4(3):382-8
pubmed: 27009402
Psychooncology. 2010 Mar;19(3):238-47
pubmed: 19319832
Support Care Cancer. 2013 Mar;21(3):757-63
pubmed: 22933132
Endocrinology. 1990 May;126(5):2398-406
pubmed: 2109685
Eur Urol. 2003 Sep;44(3):322-8
pubmed: 12932930
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
J Androl. 1990 Sep-Oct;11(5):436-45
pubmed: 2254177
J Clin Oncol. 2000 Apr;18(8):1725-32
pubmed: 10764433
J Clin Oncol. 2003 Apr 15;21(8):1513-23
pubmed: 12697875
J Clin Endocrinol Metab. 2010 Nov;95(11):4933-42
pubmed: 20702527
Andrology. 2015 Jan;3(1):13-8
pubmed: 25331158
Asian J Androl. 2018 Nov-Dec;20(6):593-599
pubmed: 30027931
Eur Urol. 2007 Nov;52(5):1448-54
pubmed: 17544206
J Endocrinol Invest. 2013 Jun;36(6):379-84
pubmed: 23047203
Asian J Androl. 2016 Jan-Feb;18(1):85-9
pubmed: 26112476
Eur J Endocrinol. 2008 Apr;158(4):561-70
pubmed: 18362304
Ann Oncol. 2013 Mar;24(3):749-55
pubmed: 23131388
Osteoporos Int. 2009 Sep;20(9):1627-30
pubmed: 19030945
J Endocrinol Invest. 2000 Nov;23(10):690-6
pubmed: 11097435
J Clin Oncol. 2014 Feb 20;32(6):571-8
pubmed: 24419125
Eur Urol Focus. 2018 Jul;4(4):591-598
pubmed: 28753832
Eur J Cancer. 2011 Nov;47(17):2585-91
pubmed: 21704509
J Androl. 2012 Sep-Oct;33(5):886-93
pubmed: 21474790
Ann Oncol. 2015 May;26(5):833-838
pubmed: 25378299
Br J Cancer. 2013 Jul 9;109(1):60-7
pubmed: 23660945
Am J Mens Health. 2018 May;12(3):628-633
pubmed: 27489147
Ann Oncol. 2015 Nov;26(11):2305-10
pubmed: 26347114
J Sex Med. 2015 Jan;12(1):210-8
pubmed: 25370897
Clin Transl Oncol. 2016 Dec;18(12):1187-1196
pubmed: 27815687
J Adolesc Health. 2010 Aug;47(2):115-25
pubmed: 20638003
Eur Urol. 2014 Jun;65(6):1095-106
pubmed: 24268506
J Urol. 2018 Oct;200(4):794-800
pubmed: 29730199
J Sex Med. 2009 Jul;6(7):1979-89
pubmed: 19453896
J Sex Med. 2016 Jun;13(6):945-54
pubmed: 27117527
Histopathology. 2017 Feb;70(3):335-346
pubmed: 27747907
Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):672-6
pubmed: 19250763
Ann Oncol. 2007 Feb;18(2):241-8
pubmed: 17060482
Andrologia. 2012 Aug;44(4):226-9
pubmed: 22248116
J Clin Endocrinol Metab. 2014 Nov;99(11):4101-8
pubmed: 25119312
Andrologia. 2012 May;44 Suppl 1:295-9
pubmed: 21729139
Eur Urol. 2016 Jul;70(1):106-119
pubmed: 26996659
Andrologia. 2016 May;48(4):425-30
pubmed: 26268684
Int J Radiat Oncol Biol Phys. 1997 Apr 1;38(1):95-102
pubmed: 9212009
Br J Cancer. 2005 Jul 25;93(2):200-7
pubmed: 15999104
J Natl Compr Canc Netw. 2012 Apr;10(4):537-44
pubmed: 22491050
J Psychosom Res. 2001 Dec;51(6):735-43
pubmed: 11750296
Andrology. 2017 Sep;5(5):898-904
pubmed: 28591464
Acta Oncol. 2007;46(4):480-9
pubmed: 17497315